Research map: Real-world evaluation of [177Lu]Lu-PSMA-617 RLT in post-taxane mCRPC: feasibility and safety of individualized treatment in a challenging cohort

Back to the article

Papers in this map

  1. Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer · Chris C. Parker · 2013 · 3413 citations · Cited by this paper
  2. Organ and tumor dosimetry of [161Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC · Andrea Schaefer-Schuler · 2026 · Cites this paper
  3. Whole-body TSPO-PET reveals stage-dependent disruption of systemic immune organ interactions in glioblastoma · 2026 · Related
  4. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer · Oliver A. Sartor · 2021 · 2844 citations · Cited by this paper
  5. Evaluation of treatment efficacy of the 161Tb- and 177Lu-Labeled GRPR antagonists AMTG and RM2 in a mouse model of prostate cancer · 2026 · Related
  6. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3 · Howard I. Scher · 2016 · 1672 citations · Cited by this paper
  7. From image reconstruction to clinical prognosis: A comprehensive analysis of centiloid-based amyloid PET assessment · 2026 · Related
  8. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study · Michael S. Hofman · 2018 · 1181 citations · Cited by this paper
  9. [18F]FDG PET during immunotherapy: mind the gap between evidence, imaging guidelines, and oncology practice · 2026 · Related
  10. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial · Michael S. Hofman · 2021 · 1159 citations · Cited by this paper
  11. CSF proteomic pathway alterations and caudate dopamine transporter deficits predict cognitive vulnerability in early Parkinson’s disease · 2026 · Related
  12. Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT) · Clemens Kratochwil · 2023 · 302 citations · Cited by this paper
  13. Skeletal muscle radiodensity as an automated survival predictor in men with metastatic castration-resistant prostate cancer undergoing PSMA-targeted radioligand therapy · 2026 · Related
  14. Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial · Michael S. Hofman · 2023 · 225 citations · Cited by this paper
  15. In vivo multimodal PET/MRI imaging and plasma biomarkers implicate glymphatic dysfunction linking neuroinflammation to tau pathology in the early Alzheimer’s disease continuum · 2026 · Related
  16. 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study) · Fadi Khreish · 2021 · 95 citations · Cited by this paper
  17. Prospective comparison of [68Ga]Ga-FAPI-04 PET/MRI, [18F]FDG PET/CT, and contrast-enhanced MRI for predicting pathologic complete response after neoadjuvant chemotherapy in breast cancer · 2026 · Related
  18. Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer · Kim N. Chi · 2024 · 34 citations · Cited by this paper
  19. 68Ga-PSMA PET/CT in biochemically recurrent prostate cancer: association with genomic data · 2026 · Related
  20. Prognostic models for predicting overall survival in metastatic castration-resistant prostate cancer: a systematic review · Mariona Pinart · 2018 · 31 citations · Cited by this paper
  21. Personalized metabolic connectome analysis reveals glucose heterogeneity in ischemic cerebrovascular disease · 2026 · Related
  22. Efficacy and Toxicity of [ 177 Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data · Vishnu Murthy · 2024 · 24 citations · Cited by this paper
  23. Impact of extended [177Lu] Lu-PSMA-617 therapy on absorbed kidney dose and CKD-EPI values: how long can therapy be safely continued? · Edanur Topal · 2025 · 14 citations · Cited by this paper
  24. Lu-177 PSMA vs Comparator Treatments and Survival in Metastatic Castration-Resistant Prostate Cancer · Yu Yang Soon · 2024 · 12 citations · Cited by this paper
  25. Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration‐resistant prostate cancer treated with Radium‐223 · Esmail Mutahar Al-Ezzi · 2021 · 11 citations · Cited by this paper

Source: OpenAlex (CC0)